Skip to main content
Top
Published in: Reactions Weekly 1/2021

01-03-2021 | Ciclosporine | Case report

Immune-globulin/rituximab/tacrolimus

Bilateral optic atrophy and lack of efficacy: case report

Published in: Reactions Weekly | Issue 1/2021

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literature
go back to reference Al-Jehani MH, et al. Cyclophosphamide as a treatment for focal segmental glomerular sclerosis recurrence in a kidney transplant patient. American Journal of Case Reports 22: 1-5, No. 1, 4 Feb 2021. Available from: URL: http://doi.org/10.12659/AJCR.929097 Al-Jehani MH, et al. Cyclophosphamide as a treatment for focal segmental glomerular sclerosis recurrence in a kidney transplant patient. American Journal of Case Reports 22: 1-5, No. 1, 4 Feb 2021. Available from: URL: http://​doi.​org/​10.​12659/​AJCR.​929097
Metadata
Title
Immune-globulin/rituximab/tacrolimus
Bilateral optic atrophy and lack of efficacy: case report
Publication date
01-03-2021
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2021
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-021-92417-x

Other articles of this Issue 1/2021

Reactions Weekly 1/2021 Go to the issue

Case report

Durvalumab

Case report

Multiple drugs

Case report

Immune globulin